
|Articles|March 15, 2004
FDA extends review of Vitrase by 90 days
Irvine, CA-The FDA is extending its review of ISTA Pharmaceuticals Inc.'s new drug application for Vitrase for use as a spreading agent by 90 days to allow for a full review.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Eyes on May 2026: A month of durable therapies, a regulatory reversal, and rethought echanisms
2
TECNIS PureSee IOL launches in US following FDA approval for cataract surgery
3
Phase 3 NORTHSTAR trial launches for gildeuretinol in stargardt disease
4
Reasoning prompts sharpen multimodal AI on bilingual ophthalmology exam questions
5





















